Emergent BioSolutions (EBS -1.9%) and Integrated BioTherapeutics enter into a joint research, development and manufacturing collaboration focused on an equine-based hyperimmunoglobulin for the treatment of hemorrhagic fever caused by Filoviruses. Under the partnership, Integrated Bio extends an exclusive global license to its proprietary vaccine antigens and know-how to EBS. Financial terms are not disclosed.
{iframe}http://seekingalpha.com/news/3224748-emergent-bio-integrated-biotherapeutics-team-develop-hyperimmunoglobulin-filovirus-associated?utoken=77cea408193abfd0b8876d8484dacaab#email_link{/iframe}